Management of Castration Resistant Prostate Cancer

Fred Saad, MD, FRCS Professor and Chief of Urology, Director of GU Oncology, University of Montreal Endowed Chair in Prostate Cancer, University of Montreal Hospital Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada. Mario A. Eisenberger, MD R. Dale Hughes Professor of Oncology and Urology, The Johns Hopkins University, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations Chapter 1 - Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities - Mario A. Eisenberger and Fred Saad Chapter 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm - Tian Zhang and Andrew J. Armstrong Chapter 3. Molecular Mechanisms of Prostate Cancer Progression after Castration - William G. Nelson and Kenneth J. Pienta Chapter 4. New Imaging Modalities - Steve Y. Cho, Seyed S. Dianat and Katarzyna Macura Part II. TREATMENT - The Androgen Receptor Signaling Axis biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals Chapter 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer - Heather H. Cheng and Bruce Montgomery Chapter 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer - Jarett L. Feldman, Dana Rathkopf and Michael J. Morris Chapter 7. Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) - Adam Siegel and Charles J. Ryan Chapter 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) - Robert J. van Soest, Ellen S. de Morree, Cora N. Sternberg and Ronald de Wit Chapter 9. The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer - Romulado Barroso-Sousa and Charles G. Drake Chapter 10. Bone Targeted Therapy: Rationale and Current Status - Benjamin A. Gartrell and Fred Saad Chapter 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer - Oliver Sartor and Brian Lewis Part III. New Drug Development: Clinical Trials Design in CRPC Chapter 12. Introduction - Aurelius Omlin, Carmel Pezaro and Johann S. de Bono Chapter 13. Phase I/II targeted treatments - Aurelius Omlin, Carmel Pezaro and Johann S. de Bono Chapter 14. Defining Clinical Endpoints in Castration-resistant Prostate Cancer - Jorge A. Garcia and Robert Dreicer Part IV. New Drug Development: Specific Targets Chapter 15. Angiogenesis Inhibition in Castration Resistant Prostate Cancer - Daniel J. George, William Kelly and Aaron Mitchell Chapter 16. Co-targeting Adaptive Survival Pathways - Amina Zoubeidi and Martin Gleave Chapter 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer - Hans J. Hammers and Emmanuel S. Antonarakis Chapter 18. PARP Inhibitors - Joaquin Mateo, Timothy A. Yap and Johann S. De Bono Chapter 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer - Petros D. Grivas and David C. Smith Chapter 20. Epigenetics in Castration Resistant Prostate Cancer - Leigh Ellis, Sheng-Yu Ku, Elena Lasorsa and Roberto Pili Chapter 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype - Himisha Beltran, Gurveen Kaur, Myriam Kossai, David M. Nanus and Scott T. Tagawa Part V. Clinical Management Aspects Chapter 22. Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management - Channing J. Paller and Thomas J. Smith Chapter 23. Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development - Jacob A. Martin and William K. Oh